Publications & Presentations
BVD Authored
AACR ANNUAL MEETING, APRIL 2023
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors
Radiation Research, March 2022 (print); December 2021 (online)
Paired 18F-Fluorodeoxyglucose (18F-FDG), and 64Cu-Copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) (64Cu-ATSM) PET scans in dogs with spontaneous tumors and evaluation for hypoxia-directed therapy
Clinical Cancer Research, January 2021 (print); October 2020 (online)
Intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors
Journal for ImmunoTherapy for Cancer, August 2018
White paper on microbial anti-cancer therapy and prevention
BMC Veterinary Research, April 2018
Identification of immunologic and clinical characteristics that predict inflammatory response to C. novyi-NT bacteriolytic immunotherapy
Veterinary Research, April 2018
Translational and Clinical Development of Clostridium novyi-NT
National Cancer Institute (NCI) Conference on Microbial-Based Cancer Therapy, July 11-12, 2017
Clostridium novyi-NT: Transitional and Clinical Development
EORTC-NCI-AACR Symposium, November 29 – December 6, 2016
Phase 1 clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer
13th International Congress on Targeted Anticancer, March 2015
Phase 1 clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced cancer
Symposium on Clinical Interventional Oncology (CIO), January 2015
Phase 1 trial of image-guided oncolysis by Clostridium novyi-NT spore inoculation: early technical insights
PLoS One, Dec 2014
MRI-monitored intra-tumoral injection of iron-oxide labeled Clostridium novyi-NT anaerobes in pancreatic carcinoma mouse model
Science Translational Medicine, August 2014
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses
World Journal of Microbiology and Biotechnology, August 2014
Evaluation of 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent